Highest-materiality recent filing
Brian C. Thomas, Ph.D. resigned from the board effective June 9, 2026, with no disagreement with the company.
Metagenomi reports $140.2M cash; MGX-001 IND on track for Q4 2026
Cash, equivalents and marketable securities of $140.2M at March 31, 2026; runway through Q4 2027.
Metagenomi reports $160.8M cash, MGX-001 on track for IND in 4Q 2026
Cash, equivalents and marketable securities $160.8M as of Dec 31, 2025; runway through 4Q 2027.
Metagenomi renames to Metagenomi Therapeutics; hemophilia A program on track for IND in 2026
Name changed to Metagenomi Therapeutics, Inc. effective Jan 12, 2026; ticker MGX unchanged.
Metagenomi Q3: $184.1M cash, 25% workforce cut, CEO change, MGX-001 data positive
Cash, equivalents, and marketable securities $184.1M as of Sep 30, 2025; runway extended into Q4 2027.
Metagenomi enters LNP license with Acuitas, terminates Affini-T TCR deal
Non-exclusive Acuitas license for LNP technology; low-seven-figure annual maintenance fee until first Phase 1 dosing.
Metagenomi reports Q2 2025 cash $205M; hemophilia A IND/CTA submission planned for 2026
Cash, cash equivalents and marketable securities of $205.0M as of June 30, 2025; runway expected into 2027.
Metagenomi stockholders elect Dr. Willard H. Dere as Class I Director and ratify PwC as auditor
Dr. Willard H. Dere elected with 7,580,903 votes for, 2,891,893 withheld, and 8,292,425 broker non-votes.
Type II nuclease MG21-1 in single AAV achieved 69% protein knockdown in mouse motor cortex and 82% in brain via systemic delivery.
Metagenomi NHP hemophilia A study shows durable FVIII activity through 19 months; Q1 cash $226M
Hemophilia A NHP study: durable FVIII activity at therapeutically relevant levels through ~19 months; final FVIII levels 80%, 10%, 32%.
Metagenomi reports $248.3M cash; hemophilia A program on track for IND in 2026
Cash, cash equivalents, and marketable securities $248.3M as of Dec 31, 2024; runway into 2027.
Metagenomi enters $75M at-the-market equity distribution agreement with Jefferies
Agreement with Jefferies to sell up to $75M of common stock via ATM offerings on Nasdaq.
Metagenomi adds Eric Bjerkholt to board; board size increases to six
Eric Bjerkholt appointed as Class II director effective Jan 27, 2025; board expands from five to six.
FVIII activity sustained across 13-16.5 months in NHPs: 72%, 9%, 30% at 16.5 mo; integration freq 0.7-3.1%.
Metagenomi nominates MGX-001 DC for hemophilia A; reports $274.6M cash; Q3 expenses down
Nominated MGX-001 as first development candidate for hemophilia A; IND-enabling activities initiated, IND filing on track for 2026.
Metagenomi reports 12-month durable FVIII activity in preclinical hemophilia A study
All three NHPs showed durable FVIII activity at 12 months: 82%, 41%, and 9%.
Metagenomi declares MGX-001 DC for hemophilia A; cash $299.9M into 2027
Declared MGX-001 as lead development candidate for hemophilia A; 12-month NHP data accelerated to September 2024.
Metagenomi Q1 net loss $25.1M, cash $327.4M; regains base editing and RIGS rights from Moderna
Q1 net loss $25.1M ($1.19/share) vs $16.1M loss in Q1 2023; collaboration revenue $11.2M.
Mutually terminated 2021 Strategic Collaboration and License Agreement with Moderna as of April 26, 2024.
Metagenomi reports FY2023 net loss of $68.3M; Hemophilia A NHP proof of concept achieved
Net loss $68.3M in FY2023; collaboration revenue $44.8M, up from $17.2M in 2022.
Metagenomi adopts amended charter and bylaws in connection with IPO
Authorized 500M shares of common stock and 10M shares of undesignated preferred stock.
On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the “Board”) of Metagenomi Therapeutics, Inc. (the “Company”) of his resignation from his position as a member of the Board, effective as of June 9, 2026.
appointed Eric Bjerkholt to serve as a director of the Board, each effective as of January 27, 2025
Max materiality 0.80 · Median 0.65 · Most common event other_material